Myeloma and plasma cell disorders service
The UHS myeloma and plasma cell disorders service is led by Dr Matthew Jenner. The service is
responsible for the management of patients with myeloma and related conditions including MGUS,
MGCS, AL amyloidosis and POEMS syndrome. There is a weekly all day myeloma clinic. The
service also sees patients referred for autologous stem cell transplant from neighbouring trusts
and works in close liaison with colleagues in the region with many patients jointly managed. There
is close working with renal, cardiac and neurology services in particular. The service has a particular
interest in genetically defined high-risk myeloma and there is ongoing research collaboration both
through clinical trials and with the Wessex Regional Genetics Laboratory in Salisbury in relation to
the impact of genetics on clinical outcomes.
The clinical trials portfolio is very active with Southampton frequently being one of the top
recruiting sites in UK Myeloma Research Alliance (UKMRA) national myeloma studies as well as
having a mixed portfolio of both early and late phase commercial clinical trials. There is
representation from Southampton both on the UKMRA and the UK Myeloma Forum. Southampton
is one of three centres that have established the Myeloma UK sponsored NIHR Myeloma
Healthcare Informatics Collaborative to collect and utilise patient data to evaluate outcomes and
improve patient care.
Myeloid disorders service
The UHS myeloid disorders service is responsible for the management of patients with a full range
of chronic myeloid disorders including MDS, MPNs and less common myeloid conditions such as
systemic mastocytosis and eosinophilias. There is a weekly multi-consultant myeloid clinic seeing
patients from Southampton and Southwest Hampshire as well as those referred from further afield
including for clinical trials. Each consultant has a particular interest in different myeloid disorders
but also manage a full range of conditions. UHS is an MDS Foundation Centre of Excellence. There
is well established collaboration with other centres both for routine clinical care and for clinical
trials.
Day case treatments including chemotherapy, transfusions and venesections are undertaken on C7
haematology day case unit under the direct supervision of a senior clinical fellow.